JAK2 and nasopharyngeal carcinoma: Furthermore, IL-6, as an upstream activator of the JAK2/STAT3 pathway, could over-activate the JAK2/STAT3 signaling pathway, promote the malignant progression of NPC, and shorten patients’ survival time when upregulated, thus providing a potential target for NPC treatment.